Pioglitazone

InterventionApproved 19994 papers2 findingsPubChem 4829ChEBI 8228MeSH D000077205

  • Humans1

Mouse lifespan

NIA ITP

Outcomes

1

Bladder cancer

no changein humans1Moderate certainty

1 study

  1. Pioglitazone has no effect on bladder cancer in humans (pooled RR ≈ 1.05, 95% CI 0.52-2.09).

    Humanstype 2 diabetes mellitus

    Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis · Urologia · 17 Sep 2026

Bladder cancer →

Associations

1

Pure-tone average

downin humans1Very low certainty

1 study

  1. Pioglitazone is associated with pure-tone average in humans.

    Humansin patients with T2DM

    Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing-Impaired Patients With Type 2 Diabetes · Pharmacology research & perspectives · 10 Sep 2026

Pure-tone average →

Trials

266

Approved

All 11

Repurposing

40 of 65

In trials

  • Glucose Metabolism Disorders

    Phase 4 · Results posted · 25 trials

  • Dyslipidemias

    Phase 4 · Completed · 22 trials

  • Lipoatrophic Diabetes Mellitus

    Phase 4 · Completed · 16 trials

  • Glucose Intolerance

    Phase 4 · Results posted · 9 trials

  • Coronary Disease

    Phase 4 · Results posted · 4 trials

  • Carotid Intimal Medial Thickness 1

    Phase 4 · Completed · 3 trials

All 18

  • Chronic Hepatitis C

    Phase 4 · Results posted · 3 trials

  • Mild Cognitive Impairment Due to Alzheimer's Disease

    Phase 3 · Terminated · 2 trials

  • Alcoholism

    Phase 2 · Terminated · 5 trials

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

    Phase 2 · Completed · 4 trials

  • Non-Small-Cell Lung Carcinoma

    Phase 2 · Terminated · 3 trials

  • Breast Neoplasms

    Phase 2 · Recruiting · 2 trials

  • Hepatitis

    Phase 2 · Results posted · 2 trials

  • Opioid-Related Disorders

    Phase 2 · Results posted · 2 trials

  • Oral Leukoplakia

    Phase 2 · Results posted · 2 trials

  • Pancreatic Neoplasms

    Phase 2 · Results posted · 2 trials

  • Recurrence

    Phase 1/2 · Status unknown · 2 trials

  • Castration-resistant prostate cancer

    Phase 1 · Completed · 1 trial

Readouts due

Stopped

  • NCT02072096 · Terminated · Type 2 diabetes

    The trial was terminated per protocol because of lack of feasibility.

  • NCT02763007 · Terminated · Type 2 diabetes

    difficulty in recruiting patients

  • NCT04416269 · Terminated · Diabetes mellitus

    The study was suspended and during this time recruitment and study activities were halted. The study was ultimately terminated in April 2026 without having re-opened for recruitment additional participants.

  • NCT00203996 · Terminated · Insulin resistance

    Did not meet target patient accrual goals

  • NCT01717040 · Terminated · Insulin resistance

    The study ended early due to budgetary issues

  • NCT00742326 · Terminated · Fatty liver

    Enrollment stopped prior to complete enrollment due to slow accrual

All 15

  • NCT01931566 · Terminated · Mild Cognitive Impairment Due to Alzheimer's Disease

    Lack of efficacy of the drug; no safety concern

  • NCT02284906 · Terminated · Mild Cognitive Impairment Due to Alzheimer's Disease

    Lack of efficacy of the drug; no safety concern

  • NCT01631630 · Terminated · Alcoholism

    The study was closed to recruitment due to feasibility problems.

  • NCT03060772 · Terminated · Alcoholism

    Study was suspended in 2020 due to COVID-19 pandemic as a result of recruitment challenges and the inability to conduct all study procedures (e.g., bronchoscopy) per protocol. In late 2021 the decision was made to not re-open the study.

  • NCT00923949 · Terminated · Non-Small-Cell Lung Carcinoma

    Study never published; terminated early due to low accrual.

  • NCT05582707 · Terminated · Cerebral hemorrhage

    Loss of Financial Sponsor

  • NCT00951379 · Terminated · Oral Leukoplakia

    Due to slow accrual.

  • NCT03860753 · Terminated · Anxiety disorders

    Halted enrollment due to COVID-19

  • NCT03080480 · Terminated · Infection

    The results are negtive.

Trial sponsors

Funding

National Institute of Diabetes and Digestive and Kidney DiseasesUS$318.4k1 grant since 2024

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 2Jul 2026: 0Aug 2026: 2Sep 2026: 3Oct 2026: 07

Related